Respiratory syncytial virus human experimental infection model: Provenance, production, and sequence of low-Passaged memphis-37 challenge virus

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Kim, Young In ^a,b   DeVincenzo, John P ^a,b   Jones, Bart G ^c   Rudraraju, Rajeev ^c,e   Harrison, Lisa ^b   Meyers, Rachel ^d   Cehelsky, Jeff ^d   Alvarez, Rene ^d,f   Hurwitz, Julia L ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d ALNYLAM PHARMACEUTICALS   (United States)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f Naval Medical Research Unit San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; NEUTRALIZING ANTIBODY; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS PROTEIN; ANTIVIRUS AGENT;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; DISEASE MODEL; DRUG SYNTHESIS; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PREDICTIVE VALUE; PROTEIN POLYMORPHISM; PROTEIN PROCESSING; PROVOCATION TEST; REPRODUCIBILITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS MEMPHIS 37; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEQUENCE HOMOLOGY; STRAIN IDENTIFICATION; VACCINE PRODUCTION; VERO CELL LINE; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PLAQUE; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; BRONCHIOLITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHLOROCEBUS AETHIOPS; GENETICS; HEPG2 CELL LINE; HOST PATHOGEN INTERACTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; MALE; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME; UNITED STATES; VIROLOGY;

RESPIRATORY SYNCYTIAL VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIVIRAL AGENTS; BRONCHIOLITIS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; CHILD, PRESCHOOL; EPITOPES, T-LYMPHOCYTE; HEP G2 CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SEQUENCE HOMOLOGY, AMINO ACID; TENNESSEE; TREATMENT OUTCOME; VERO CELLS; VIRAL PROTEINS;

EID: 84913590251     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113100     Document Type: Article

References (44)

1. Glezen WP, Taber LH, Frank AL, Kasel JA (1986) Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 140: 543-546.
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, et al. (2010) Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and metaanalysis. Lancet 375: 1545-1555.
3. DeVincenzo JP, Cehelsky J, Meyers R, Vaishnaw A, Nochur S, et al. (2007) Development of a human experimental infection model of Respiratory Syncytial Virus. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Abstract # V-1257 Chicago, IL.
4. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, et al. (2010) Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182: 1305-1314.
5. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, et al. (2014) Oral GS- 5806 Activity in a Respiratory Syncytial Virus Challenge Study. N Engl J Med 371: 711-722.
6. Ackermann MR (2014) Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. ILAR J 55: 4-15.
7. Derscheid RJ, van Geelen A, Gallup JM, Kienzle T, Shelly DA, et al. (2014) Human respiratory syncytial virus memphis 37 causes acute respiratory disease in perinatal lamb lung. Biores Open Access 3: 60-69.
8. Grosz DD, van Geelen A, Gallup JM, Hostetter SJ, Derscheid RJ, et al. (2014) Sucrose stabilization of Respiratory Syncytial Virus (RSV) during nebulization and experimental infection. BMC Res Notes 7: 158.
9. Derscheid RJ, van Geelen A, McGill JL, Gallup JM, Cihlar T, et al. (2013) Human Respiratory Syncytial Virus Memphis 37 Grown in HEp-2 Cells Causes more Severe Disease in Lambs than Virus Grown in Vero Cells. Viruses 5: 2881-2897.
10. Eyles JE, Johnson JE, Megati S, Roopchand V, Cockle PJ, et al. (2013) Nonreplicating vaccines can protect african green monkeys from the memphis 37 strain of respiratory syncytial virus. J Infect Dis 208: 319-329.
11. DeVincenzo JP (2004) Natural infection of infants with respiratory syncytial virus subgroups A and B: A study of frequency, disease severity, and viral load. Pediatr Res 56: 914-917.
12. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, et al. (2005) Comparison of a realtime reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol 43: 2356-2362.
13. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, DeVincenzo JP (2011) Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204: 996-1002.
14. Lo MS, Brazas RM, Holtzman MJ (2005) Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79: 9315-9319.
15. Stec DS, Hill MG III, Collins PL (1991) Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology 183: 273-287.
16. Fuentes S, Tran KC, Luthra P, Teng MN, He B (2007) Function of the respiratory syncytial virus small hydrophobic protein. J Virol 81: 8361-8366.
17. Fix J, Galloux M, Blondot ML, Eleouet JF (2011) The insertion of fluorescent proteins in a variable region of respiratory syncytial virus L polymerase results in fluorescent and functional enzymes but with reduced activities. Open Virol J 5: 103-108.
18. Reiche J, Schweiger B (2009) Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007. J Clin Microbiol 47: 1800-1810.
19. Frabasile S, Delfraro A, Facal L, Videla C, Galiano M, et al. (2003) Antigenic and genetic variability of human respiratory syncytial viruses (group A) isolated in Uruguay and Argentina: 1993-2001. J Med Virol 71: 305-312.
20. Sato M, Saito R, Sakai T, Sano Y, Nishikawa M, et al. (2005) Molecular epidemiology of respiratory syncytial virus infections among children with acute respiratory symptoms in a community over three seasons. J Clin Microbiol 43: 36-40.
21. Levine S, Klaiber-Franco R, Paradiso PR (1987) Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus. J Gen Virol 68 (Pt 9): 2521-2524.
22. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, et al. (2001) CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2: 732-738.
23. Harcourt J, Alvarez R, Jones LP, Henderson C, Anderson LJ, et al. (2006) Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J Immunol 176: 1600-1608.
24. Zhang W, Choi Y, Haynes LM, Harcourt JL, Anderson LJ, et al. (2010) Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J Virol 84: 1148-1157.
25. Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, et al. (2012) Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol 25: 193-203.
26. Martinez I, Dopazo J, Melero JA (1997) Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. J Gen Virol 78 (Pt 10): 2419-2429.
27. Zimmer G, Conzelmann KK, Herrler G (2002) Cleavage at the furin consensus sequence RAR/ KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture. J Virol 76: 9218-9224.
28. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537.
29. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, et al. (2014) Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Virology 454-455: 139-144.
30. American Academy of Pediatrics, Infectious diseases and bronchiolitis guidelines committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134: 415-420.
31. Grad YH, Newman R, Zody M, Yang X, Murphy R, et al. (2014) Within-Host Whole-Genome Deep Sequencing and Diversity Analysis of Human Respiratory Syncytial Virus Infection Reveals Dynamics of Genomic Diversity in the Absence and Presence of Immune Pressure. J Virol 88: 7286-7293.
32. McLellan JS, Chen M, Leung S, Graepel KW, Du X, et al. (2013) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340: 1113-1117.
33. Levely ME, Bannow CA, Smith CW, Nicholas JA (1991) Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. J Virol 65: 3789-3796.
34. de Graaff PM, Heidema J, Poelen MC, van Dijk ME, Lukens MV, et al. (2004) HLA-DP4 presents an immunodominant peptide from the RSV G protein to CD4 T cells. Virology 326: 220-230.
35. Heidema J, de Bree GJ, de Graaff PM, van Maren WW, Hoogerhout P, et al. (2004) Human CD8(+) T cell responses against five newly identified respiratory syncytial virus-derived epitopes. J Gen Virol 85: 2365-2374.
36. van Bleek GM, Poelen MC, van der Most R, Brugghe HF, Timmermans HA, et al. (2003) Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells. J Virol 77: 980-988.
37. Brandenburg AH, de Waal L, Timmerman HH, Hoogerhout P, de Swart RL, et al. (2000) HLA class Irestricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. J Virol 74: 10240-10244.
38. Goulder PJ, Lechner F, Klenerman P, McIntosh K, Walker BD (2000) Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J Virol 74: 7694-7697.
39. Rock MT, Crowe JE Jr (2003) Identification of a novel human leucocyte antigen-A.∗01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Immunology 108: 474-480.
40. Venter M, Madhi SA, Tiemessen CT, Schoub BD (2001) Genetic diversity and molecular epidemiology of respiratory syncytial virus over four consecutive seasons in South Africa: identification of new subgroup A and B genotypes. J Gen Virol 82: 2117-2124.
41. Olson MR, Varga SM (2008) Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines 7: 1239-1255.
42. Kumaria R, Iyer LR, Hibberd ML, Simoes EA, Sugrue RJ (2011) Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children. Virol J 8: 372.
43. Rebuffo-Scheer C, Bose M, He J, Khaja S, Ulatowski M, et al. (2011) Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010. PLoS One 6: e25468.
44. Karron RA, Buonagurio DA, Georgiu AF, Whitehead SS, Adamus JE, et al. (1997) Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A 94: 13961-13966.